Indications and Purposes
| 1 Indications And Usage Cinqair ® Is Indicated For The Add-On Maintenance Treatment Of Patients With Severe Asthma Aged 18 Years And Older With An Eosinophilic Phenotype [See Clinical Studies ( 14 )] . Limitation Of Use: Cinqair Is Not Indicated For Treatment Of Other Eosinophilic Conditions. Cinqair Is Not Indicated For The Relief Of Acute Bronchospasm Or Status Asthmaticus [See Warnings And Precautions ( 5.2 )] . Cinqair Is An Interleukin-5 Antagonist Monoclonal Antibody (Igg4 Kappa) Indicated For Add-On Maintenance Treatment Of Patients With Severe Asthma Aged 18 Years And Older, And With An Eosinophilic Phenotype ( 1 ). Limitations Of Use : Cinqair Is Not Indicated For: Treatment Of Other Eosinophilic Conditions ( 1 ) Relief Of Acute Bronchospasm Or Status Asthmaticus ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Reslizumab |